Abstract: AIM: To evaluate the clinical efficacy and safety of the shexiang xintongning tablets in treatment of patients with coronary heart disease and angina pectoris.METHODS: 206 subjects were involved in a multi-center, randomized, double-blinded, double-simulation and positive drug parallel-controlled clinical trail, and the trial group was treated with the shengxiang xintongning tablets, the control group was treated with the xinkeshu tablets.Among them, 103 patients were enrolled in experimental group, while 103 cases enrolled in the control group.RESULTS: The total therapeutic effective rate of the experimental group has reached 90.29%, and was significantly better than that in the control group which has reached 75.91% (P <0.01).There was a significant decrease on the score of symptoms of the traditional Chinese medicine in trial group in comparison with those in control group (P <0.01).CONCLUSION: The shengxiang xintongning tablet is an effective drug against coronary heart disease and angina pectoris and no side-effect was found.

Key words: shengxiang xintongning tablet, coronary heart disease and angina pectoris, TCD therapy, clinical trial